医学
耐受性
全身疗法
肿瘤科
护理标准
肝细胞癌
内科学
临床试验
重症监护医学
卡波扎尼布
靶向治疗
癌症
不利影响
乳腺癌
作者
Arndt Vogel,Melanie Bathon,Anna Saborowski
标识
DOI:10.1080/14737140.2021.1882855
摘要
Introduction: Hepatocellular carcinoma (HCC) is one of the most common and deadliest cancers worldwide. In recent years, several drugs have been approved in first- and second-line setting. Currently, several phase-III trials are ongoing with combinations of checkpoint inhibitors, tyrosine kinase inhibitors (TKI) and anti-angiogenic antibodies, which will most likely increase therapeutic options in frontline therapy in the near future.Areas covered: This review summarizes the standard of care in first-line systemic therapy for patients with advanced HCC and provides an outlook on the most promising combinations currently tested in prospective trials.Expert opinion: The recent approval of novel substances has substantially changed the field of palliative treatment strategies in patients with advanced HCC. Immuno-oncology (IO)-based combination therapies will become the next standard of care in frontline HCC. The potent anti-tumor efficacy and good tolerability of these therapies will increase the use of upfront systemic therapy in patients with intermediate stage HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI